MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target?

Q3 Pharmacology, Toxicology and Pharmaceutics

Infectious disorders drug targets Pub Date : 2023-01-01 DOI:10.2174/1871526522666220619121539

Sultan Almuntashiri, Duo Zhang, Payaningal R Somanath, Andrea Sikora

引用次数: 0

Abstract

Identifying novel therapies is a critical need in the treatment of coronavirus disease-19 (COVID-19) and acute respiratory distress syndrome (ARDS). Stromelysin-1, also known as matrixmetalloproteinase 3 (MMP3), has been investigated as a diagnostic biomarker and a potential pharmacological target. Here, we discuss the recent findings of Gelzo et al. in the context of additional MMP3 investigations to delineate its exact role in diagnosis, prognostication, and phenotyping, in addition to its promising role as a therapeutic target in COVID-19-associated respiratory failure.

查看原文本刊更多论文

重症新冠肺炎患者MMP3：生物标志物还是治疗靶点？

识别新疗法是治疗冠状病毒疾病19（新冠肺炎）和急性呼吸窘迫综合征（ARDS）的关键需求。基质金属蛋白酶-1，也称为基质金属蛋白酶3（MMP3），已被研究为诊断生物标志物和潜在的药理学靶点。在这里，我们讨论了Gelzo等人的最新发现。在额外的MMP3研究的背景下，以描述其在诊断、预后和表型中的确切作用，以及其作为COVID-19相关呼吸衰竭的治疗靶点的有希望的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

3.10

自引率

0.00%

发文量

123

期刊介绍： Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.